In vivo application of non-viral vectors to the liver

Paul Richardson, Betsy T. Kren, Clifford J Steer

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The liver plays a central role in many inherited and acquired genetic disorders, and thus is a potential target for nucleic acid therapies. Despite the great strides made in basic molecular biology over the last two decades successful gene therapy remains elusive. Most recently, there has been considerable effort to develop non-viral gene therapy approaches, in part, to overcome the potential complications associated with viral delivery systems. This review outlines the different non-viral approaches available to the liver, and includes a detailed review of recent advances in delivery vectors for use in techniques such as gene augmentation, with particular emphasis on useful applications of antisense and ribozyme technology.

Original languageEnglish (US)
Pages (from-to)123-131
Number of pages9
JournalJournal of Drug Targeting
Issue number2
StatePublished - 2002

Bibliographical note

Funding Information:
Paul Richardson is supported by the Wellcome Trust. This work was funded in part by National Institutes of Health Grants P01 HD32652-06 (to B.T.K), P01 HL65578-01 (to C.J.S.), and ValiGen, Inc. (to C.J.S.).


  • DNA
  • Liposomal formulations
  • Mitochondrial
  • Non-viral delivery
  • Polyethylenimine


Dive into the research topics of 'In vivo application of non-viral vectors to the liver'. Together they form a unique fingerprint.

Cite this